ORTHOVISC® & MONOVISC® High Molecular Weight Hyaluronan demonstrated statistically and clinically significant symptom improvement in patients with knee osteoarthritis.¹

Visit us online: www.orthovisc.com

¹. ORTHOVISC® and MONOVISC® are indicated in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g., acetaminophen. Clinical studies, the most commonly reported adverse events for ORTHOVISC were arthralgia, back pain, and headache. Other side effects included local injection site adverse events. In clinical studies, the most commonly reported adverse events for MONOVISC were arthralgia, joint swelling and injection site pain. ORTHOVISC and MONOVISC are contraindicated in patients with known hypersensitivity to hyaluronate formulations or known hypersensitivity (allergy) to gram positive bacterial proteins. ORTHOVISC and MONOVISC should not be injected in patients with infections or skin diseases in the area of the injection site or joints. MONOVISC should not be administered to patients with known bleeding disorders. Intradermal injection of sodium hyaluronate preparations has occasionally been associated with allergic reactions and transient hypotension which have generally resolved spontaneously or after conservative treatment.